16.2 C
Tuesday, July 16, 2024

IntegriChain Acquires BridgeView, Creating Top Pharma Data Solution

Must read

The combined entity delivers the ICyte revenue optimization platform, which is powered by first-party data, AI-enabled data exploration, and field intelligence and alerting.

IntegriChain, delivering pharma’s comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced the acquisition of BridgeView Data Solutions, the commercial data warehouse and data aggregation assets of BridgeView Life Sciences LLC (formerly Coeus Solutions).

This transaction allows IntegriChain and BridgeView to offer pharmaceutical manufacturers best-in-class first- and third-party data aggregation, add AI-assisted data exploration capabilities, extend its reach through field intelligence and alerting, deliver new commercial data warehouse (CDW) offerings, and deepen its strength in commercial data strategy.

“Pharma is under pressure to improve profitability like never before,” said Josh Halpern, CEO of IntegriChain. “Legacy commercial strategies and commercial decision support have resulted in an industry outlook of flat to down net revenue. To return to profitable growth, manufacturers need to connect the back and front of the house – starting with their commercial, financial, and operational data.

We are thrilled to join forces with BridgeView Data Solutions to deliver the first platform that meets the needs of the pharmaceutical industry by integrating all the third-party and first-party data that drive both commercial execution and the net revenue cycle. Together, we will deliver analytics that can transform the bottom-line impact of access, affordability, patient service, channel, and field investments.

For IntegriChain, this is a very synergistic sixth acquisition—and the first following our partnership with Nordic Capital—as we execute our ambitious growth targets and help pharmaceutical manufacturers bring their science to market.

“High-quality first-party data – especially first-party patient-level data – is increasingly essential to day-to-day commercial and operational execution. More and more use cases require commercial first- and third-party data to flow back into net revenue business processes and net revenue first-party data to flow forward into commercial decisions,” said Mike Zubey, CEO of BridgeView Life Sciences. “IntegriChain has established itself as an innovator in net revenue optimization. We are excited to join IntegriChain’s family and platform and to be an integral part of embedding our combined capabilities in pharma’s commercial execution.”

Combined data offerings

IntegriChain will offer BridgeView’s DataBridge™ commercial data warehouse, delivering a flexible, scalable data synthesis, enrichment, and application platform. DataBridge ingests, stores, governs, and analyzes data from heterogeneous sources, including existing databases, business applications, and industry-standard solutions.

By harmonizing and enriching disparate information flows, DataBridge equips commercial stakeholders with the right insights faster through accurate ad-hoc analysis, rapid BI reporting, and advanced data science enabled by AI/ML technology. IntegriChain will connect its ICyte net revenue optimization platform and DataBridge to drive profitable insights for manufacturers.

Also Read: 10 Cutting-edge Data Protection Solutions: AI, Encryption and Beyond

IntegriChain will integrate key features of BridgeView’s specialty data aggregation platform into ICyte Patient Data Solutions. BridgeView’s AI-powered data exploration, field intelligence, and patient journey alerting—via popular CRM systems, including Veeva Vault CRM Suite—perfectly complement IntegriChain’s ICyte patient mastering and patient journey analytics to deliver best-in-class data aggregation to the Pharmaceutical industry.

Under the agreement, IntegriChain acquired all of BridgeView Life Sciences, LLC’s data solutions assets. The entire Data Solutions leadership and professional team will join IntegriChain’s global workforce of nearly 750 professionals. BridgeView customers should expect no changes or interruptions to the delivery of their solutions and servicing of their accounts. This acquisition is IntegriChain’s sixth expansion and the first since entering its strategic partnership in 2023 with Nordic Capital, a leading sector-specialized private equity investor with a broad Healthcare, Pharma, and Technology portfolio.

More articles

Latest posts